Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiac Biotech SolutionsCBSC EV-to-OCF is -16.46 as of Jul. 15, 2026. Among 855 Medical Devices & Instruments companies, Cardiac Biotech Solutions ranks better than 85.03% on this metric.
The historical rank and industry rank for Cardiac Biotech Solutions's EV-to-OCF or its related term are showing as below:
CBSC'
s EV-to-OCF Range Over the Past 10 Years
Min: -28.06 Med: -8.78 Max: -2.96
Current: -16.46
During the past 5 years, the highest EV-to-OCF of Cardiac Biotech Solutions was -2.96. The lowest was -28.06. And the median was -8.78.
CBSC's EV-to-OCF is ranked better than 85.03% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 7.74
vs CBSC: -16.46
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cardiac Biotech Solutions's PE Ratio (TTM) for today is calculated as:
Cardiac Biotech Solutions's share price for today is $0.03.
Cardiac Biotech Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cardiac Biotech Solutions EV-to-OCF Related Terms
Cardiac Biotech Solutions EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiac Biotech Solutions EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cardiac Biotech Solutions's EV-to-OCF falls into.
Cardiac Biotech Solutions's current Enterprise Value is $5.30 Mil.
Cardiac Biotech Solutions's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiac Biotech Solutions (CBSC) has a EV-to-OCF of -16.46 as of Jul. 15, 2026. According to the industry distribution chart, Cardiac Biotech Solutions ranks #128 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 15%.
Is Cardiac Biotech Solutions' EV-to-OCF too high?
Cardiac Biotech Solutions' current EV-to-OCF is -16.46. Based on the distribution chart, Cardiac Biotech Solutions ranks #128 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cardiac Biotech Solutions' EV-to-OCF compare to LUCY and NXGL?
According to the Medical Devices & Instruments industry distribution chart, Cardiac Biotech Solutions ranks #128 out of 855 companies for EV-to-OCF. This places Cardiac Biotech Solutions in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.74, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiac Biotech Solutions's current EV-to-OCF is -16.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current EV-to-OCF of -16.46. The current EV-to-OCF is -16.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current EV-to-OCF is -16.46 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBSC has been successfully added to your 
